All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know AML.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, Syndax, Thermo Fisher Scientific, Kura Oncology, and AbbVie. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View AML content recommended for you
Three FLT3 inhibitors are currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of FLT3-mutated (FLT3m) acute myeloid leukemia (AML): quizartinib for newly diagnosed (ND) FLT3-internal tandem duplication (FLT3-ITD) AML and as maintenance therapy; gilteritinib for relapsed/refractory (R/R) FLT3m AML; and midostaurin for ND FLT3m AML and as maintenance therapy in FLT3m AML.1–6 Ongoing clinical trials aim to address remaining questions in the FLT3 inhibitor treatment landscape, including how these agents can be optimally integrated into treatment strategies across different clinical settings and patient populations.
The AML Hub was pleased to speak with Mark J. Levis, Charles Craddock, and Eytan Stein to gain their expert insights on the current clinical landscape for the treatment of FLT3m AML, how clinical trials are addressing the key ongoing questions, and what the future might hold for the evolution of FLT3 inhibitors in the treatment of AML.
.webp)
The AML Hub was pleased to speak with Dr Mark J. Levis about the current clinical landscape of FLT3 inhibitors in the treatment of AML and key insights from clinical trials to date.
.webp)
The AML Hub was pleased to speak with Charles Craddock about the key ongoing questions in FLT3-mutated AML and how ongoing trials are addressing these.
.webp)
The AML Hub was pleased to speak with Dr Eytan Stein about what the future might hold for FLT3 inhibitors in the treatment of acute myeloid leukemia (AML).
This educational resource is independently supported by Daiichi Sankyo. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Which AML-related topic do you currently need the most practical guidance on?
Charles Craddock
Eytan Stein
Mark J. Levis